Can-Fite Biopharma Ltd CANF Stock Analysis
- NYSE American
- Stock
- Market closed · opens Monday 9:30 AM ET
$1.95 unchanged on Oct 14
Last price · Previous close $1.95
- Market cap
- At the last price
- P/E ratio
- On last 12 months’ EPS
- Diluted EPS
- Last 12 months
- Dividend yield
- Last 12 months
Price chart
$1.95unchangedWed, Oct 14 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$1.95Oct 13
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Valuation
Financials
Dividends
About Can-Fite Biopharma Ltd
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of MASH a Phase III trial for hepatocellular carcinoma (HCC), and the Company is planning a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date.
- Sector
- Industry
- Headquarters
- Exchange
- NYSE American
- Asset type
- Common stock
- Price history since
CANF news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
CANF stock FAQ
What is CANF stock’s price today?
Can-Fite Biopharma (CANF) traded at $1.95 as of , unchanged from the previous close of $1.95.
What exchange does CANF trade on?
Can-Fite Biopharma trades on the NYSE American under the ticker symbol CANF. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.